QuidelOrtho Corporation (Nasdaq: QDEL) unites the power of Quidel Corporation and Ortho Clinical Diagnostics behind a shared mission of developing and manufacturing innovative technologies that raise the performance of diagnostic testing and create better patient outcomes across the entire healthcare continuum.
Ranked among the world’s largest in vitro diagnostics (IVD) providers, QuidelOrtho is building on more than 120 years of collective experience and innovation. We combine industry-leading expertise in immunoassay and molecular testing with a global footprint in point-of-care settings, clinical labs and transfusion medicine to advance critical diagnostic solutions at scale.
Headquartered in San Diego, our company has a rich heritage of innovation and invention. We were a pioneer in women’s health diagnostics, developing the earliest lateral-flow pregnancy test strips. We introduced the first FDA approved rapid antigen diagnostic test for Influenza A and Influenza B and launched the first-ever product to determine Rh+ or Rh- blood type. We also developed the world’s first tests for the detection of antibodies against HIV and hepatitis C. We engineered a patented dry-slide technology that has been revolutionary in both reducing the cost and extending the reach of IVD testing. And we stood at the forefront of diagnostics innovation throughout the coronavirus pandemic, developing one of the earliest molecular PCR assays for SARS-CoV-2, the first FDA emergency use authorized rapid antigen test that delivers results in 15 minutes, and high-volume antibody and antigen tests for COVID-19.
Today, QuidelOrtho’s comprehensive product portfolio covers a wide range of point-of-care tests for infectious diseases, critical cardiac health and autoimmune biomarkers, and a host of clinical and at-home products to detect COVID-19. Our sophisticated yet simple-to-use point-of-care tests enable clinicians to chart a course of treatment and empower people to take charge of their health.
We also have well-established track records for providing high-quality products and services to the global clinical laboratory and immunohematology communities. Hospitals, hospital networks, clinical laboratories and blood banks around the world depend on our innovative technology and tools (including our exclusive dry-slide technology) to help ensure test results are fast, accurate, and reliable. Our customized solutions deliver affordability, efficiency, and automation – all supported by an award-winning, service and support program that provides best-in-class technical, field, and remote service in more than 130 countries and territories around the globe.
Our core competencies and capabilities include immunoassay development, automated manufacturing, monoclonal antibody characterization and development, molecular assay development, lab-based in vitro diagnostics, blood bank solutions and transfusion pre-screening. Our current products fall generally into these categories: (1) visually-read lateral flow, where we are market leaders in infectious disease and reproductive health; (2) direct fluorescent antibodies (DFA), with expertise in infectious disease and virology; (3) micro-titer production, with a focus on bone and complement pathway markets; (4) fluorescent immunoassay products (Sofia®); (5) molecular diagnostic products including our flagship Savanna®, an integrated molecular diagnostic system; (6) immunodiagnostics, clinical chemistry and integrated testing systems to serve diagnostic labs of all sizes (VITROS® Systems); (7) immunodiagnostic donor screening systems and services that drive blood safety (Ortho Summit/VERSEIA®/VITROS® Systems); (8) industry-leading pre-transfusion testing that automates blood bank workload (ORTHO VISION Systems) with software to standardize operations, simplify tasks, and improve productivity (ORTHO CONNECT®); and (9) the industry-leading, award-winning combination of service, expertise, technology and data-driven solutions that drives effective, efficient labs (Ortho Care® Services & Informatics).
Spanning the full spectrum of customers and care – from the largest labs and hospitals to the smallest clinics and in our homes– our diverse suite of diagnostic solutions expand access to reliable answers, providing critical information when and where it is needed most. Inspired by a spirit of service, the QuidelOrtho family is committed to enhancing the wellbeing of people worldwide and happy in the knowledge we are making a difference.
QuidelOrtho was created in business combination of Quidel and Ortho Clinical Diagnostics in 2022.
The Company’s corporate office is located at 9975 Summers Ridge Road, San Diego, CA 92121.
This information can be found in the “Corporate Governance” section of our website.
Ernst & Young LLP 4370 La Jolla Village Drive, Suite 500 San Diego, CA 92101
Transfer Agent Website: www.computershare.com Telephone inquiries: 1-800-736-3001, option 1 (U.S.) or 1-781-575-3100, option 1 (non-U.S.) E-mail inquiries: web.queries@computershare.com
To request information, please fill out and submit the form below:
Personal Information Required fields denoted by an asterisk (*).
To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.
At QuidelOrtho Corporation, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.
By providing your email address below, you are providing consent to QuidelOrtho Corporation to send you the requested Investor Email Alert updates.
* Required
For further information on how we protect your information, please refer to our Privacy Policy.
To opt-out of investor email alerts, please enter your email address in the field below and you will be removed for ALL investor email alerts that you are subscribed to. After submitting your email, you will receive a confirmation email to the requested email address. You must click the confirmation link in order to complete your unsubscription. You can re-sign up for investor alerts at any time you would like.